Article Text

PDF
P13 Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials
  1. PW Noble1,
  2. C Albera2,
  3. WZ Bradford3,
  4. U Costabel4,
  5. I Glaspole5,
  6. MK Glassberg6,
  7. DJ Lederer7,
  8. Z Lin3,
  9. SD Nathan8,
  10. CA Pereira9,
  11. JJ Swigris10,
  12. D Valeyre11,
  13. L Lancaster12
  1. 1Cedars Sinai Medical Center, Los Angeles, USA
  2. 2University of Turin, Turin, Italy
  3. 3InterMune, Inc. (A Wholly Owned Roche Subsidiary), Brisbane, USA
  4. 4Ruhrlandklinik, Essen, Germany
  5. 5Alfred Hospital, Melbourne, Australia
  6. 6University of Miami Miller School of Medicine, Miami, USA
  7. 7Columbia University, New York, USA
  8. 8Inova Fairfax Hospital, Falls Church, USA
  9. 9Paulista School of Medicine, Federal University, Sao Paulo, Brazil
  10. 10National Jewish Health, Denver, USA
  11. 11Avicenne Univsersity Hospital, Bobigny, France
  12. 12Vanderbilt University Medical Center, Nashville, USA

Abstract

Introduction and objectives IPF is a chronic, progressive and irreversible disease that requires long-term clinical management. To further evaluate the clinical safety of pirfenidone in patients with IPF, we performed a comprehensive integrated analysis of safety data from 5 clinical trials.

Methods All patients assigned to receive pirfenidone (2403 mg/d) in the Phase 3 ASCEND (016) and CAPACITY (004/006) studies and all patients receiving ≥1 dose of pirfenidone in either of two ongoing open-label studies (studies 002 and 012) comprised the integrated population. EAP (002) is a compassionate use study in the U.S.; RECAP (012) is evaluating pirfenidone in patients who completed one of the Phase 3 studies. Analyses were based on the January 15, 2014 interim data cut.

Results 1299 patients were included in the integrated population. The cumulative total exposure to pirfenidone was 3160 person exposure years (PEY). The median duration of exposure was 1.7 years (range, 1 week–9.9 years); 545 (42%) patients received pirfenidone for ≥2 years and 325 (25%) patients received pirfenidone for ≥4 years. The majority of patients (75.8%) received a mean daily dose of ≥1800 mg. Consistent with prior observations, gastrointestinal and skin-related events were among the most common treatment emergent adverse events (Table 1); these were almost always mild to moderate in severity, reversible with dose modification and rarely led to treatment discontinuation. Cough, dyspnoea and IPF were the most common respiratory adverse events in the integrated population—a finding that is consistent with expectations in patients with a chronic progressive respiratory disease followed over a long period of observation. Aminotransferase (ALT or AST) elevations (>3 × ULN) occurred in 40/1299 (3.0%) patients in the integrated population.

Abstract P13 Table 1

Treatment emergent adverse events in the integrated population compared with the pooled pirfenidone 2403 mg/d and placebo groups in the Phase 3 trials*

Conclusions A comprehensive integrated analysis of safety outcomes in a large, well–defined cohort of 1299 patients with IPF who were treated with pirfenidone for up to 9.9 years demonstrated that treatment with pirfenidone is safe and generally well tolerated. These observations provide further evidence to support the long-term clinical safety of pirfenidone in patients with IPF.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.